Memphis Pharmaceuticals & Chemical Industries (EGX: MPCI)

EGX: MPCI Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	307.55	191.46	90.44	74.09	41.81	17.41
Depreciation & Amortization	19.71	12.18	-	-	-	9.68
Other Operating Activities	-183.45	-20.43	-32.5	-37.62	-38.33	-30.27
Operating Cash Flow	143.82	183.21	57.94	36.47	3.47	-3.18
Operating Cash Flow Growth	-67.21%	216.20%	58.88%	950.33%	-	-
Capital Expenditures	-26.73	-24.37	-11.45	-12.92	-2.07	-0.8
Other Investing Activities	82	54.97	10.87	7.69	4.68	2.53
Investing Cash Flow	55.27	30.59	-0.58	-5.24	2.62	1.73
Long-Term Debt Issued	-	174.7	2.34	-	-	-
Net Debt Issued (Repaid)	140.95	174.7	2.34	-	-	-
Common Dividends Paid	-12.17	-12.17	-	-	-0.25	-
Financing Cash Flow	128.78	162.53	2.34	-	-0.25	-
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-	-0
Net Cash Flow	327.87	376.33	59.7	31.23	5.84	-1.45
Free Cash Flow	117.09	158.83	46.49	23.55	1.4	-3.98
Free Cash Flow Growth	-72.61%	241.66%	97.45%	1578.00%	-	-
Free Cash Flow Margin	10.75%	18.22%	7.00%	4.27%	0.27%	-0.82%
Free Cash Flow Per Share	20.82	28.24	8.26	4.19	-	-0.71
Cash Interest Paid	19.54	14.26	36.79	-	-	0
Cash Income Tax Paid	29.3	24.84	22.41	7.04	9.38	7.01
Levered Free Cash Flow	224.48	279.99	36.76	-5.31	-1.42	33.2
Unlevered Free Cash Flow	233.39	288.9	36.76	-5.31	-1.42	33.2
Change in Net Working Capital	-47.83	-185.17	11.72	35.54	20.69	-17.06

Source: S&P Capital IQ. Standard template. Financial Sources.